Quick ReadPlain-language overview · read this first
STERIS does the healthcare system's infection prevention and compliance infrastructure: hospital instrument cleaning and disinfection, consumables/equipment/services for surgery and endoscopy, third-party sterilization for device and pharmaceutical customers (AST), and sterile-manufacturing assurance. Demand is tightly tied to medical procedure volumes, device output, and sterile production, and is stable over the long run; FY2026 revenue was about $5.936 billion, with a high share coming from services and consumables, giving better cash-flow predictability than a pure-equipment company.
The analyst assigns a Watch rating. The logic is direct: this is a good company in a good industry, but what you buy today is a good company, not a cheap one. The moat comes from scale, validation and compliance, the service network, and customer switching costs, with AST operating more than 60 sterilization and lab facilities worldwide; FY2026 operating cash flow was $1.341 billion and free cash flow $983 million, and the balance sheet is on the steady side after deleveraging. What caps the valuation is EO (ethylene oxide) regulation and litigation, plus the heavy goodwill and amortization left by M&A.
On valuation, the current price corresponds to about 27.2x FY2026 diluted EPS and 21.5x free cash flow, with an FCF yield of about 4.7%, only slightly above the same day's 4.45% 10-year Treasury. The analyst gives three tiers — bear $160-185, base $190-230, bull $240-285 — with the current price landing in the upper-middle of the neutral range, an unremarkable margin of safety. The conclusion: existing holders can keep holding, and those who don't own it are better off waiting; the preferred buy range is $165-190.
LeadA leader in infection-prevention and sterilization infrastructure with solid cash flow and a fairly stable moat, but at roughly $215.4 the price sits in the upper-middle of the neutral valuation range with an insufficient margin of safety; bear 160-185 / base 190-230 / bull 240-285, preferred buy range 165-190. Rating Watch: a good company at a good-not-cheap price.
Prices in the article are as of publication; see the valuation band above for the live price.
Bottom Line Up Front
My preliminary rating is Watch. If you already own it, I see this as closer to a "keep holding, but don't chase or add up here" name; if you have not built a position, then from a long-term business owner's perspective, STERIS is a high-quality, understandable business with decent cash flow and a fairly stable moat, but the current price does not offer a wide enough margin of safety. As of 2026-05-28/29, STE traded at roughly $215.4, with a market cap of about $21.1 billion; based on the company's full-year FY2026 results, that is about 27.2x FY2026 diluted EPS and 21.5x FY2026 free cash flow, implying a free-cash-flow yield of about 4.7%, only slightly above the 4.45% yield on the U.S. 10-year Treasury that same day and below the 5.53% Moody's Aaa corporate bond yield on 2026-05-27. This tells you the market has already priced in the "good company" part, but "cheap" is not obvious.
There are four core judgments. First, STERIS's business is essentially "infection prevention and compliance infrastructure": cleaning and disinfecting hospital instruments, consumables/equipment/services tied to surgery and endoscopy, third-party sterilization, and sterility assurance in pharmaceutical and bioprocessing environments. This kind of demand is closely tied to medical procedure volumes, single-use device output, and sterile pharmaceutical manufacturing, and is stable over the long run. Second, the company's most valuable asset is its bundled solutions, service network, validation and compliance capabilities, and global sterilization infrastructure, rather than any single product. Third, the company's cash-flow quality is good: FY2026 operating cash flow of $1.341 billion and free cash flow of $983 million, and the balance sheet, after deleveraging, is far steadier than at the peak of its M&A cycle. Fourth, what really caps the valuation is EO regulatory/litigation uncertainty and the lack of return upside at the current price.
On margin of safety, my view is that it is not obvious. Under the bear-base-bull valuation ranges given below, the current price looks more like the "reasonable-to-upper" band than "significantly undervalued." For a balanced, somewhat conservative long-term investor, this usually means the company is worth studying and tracking, but a better entry point often matters more than a better story.
As for which type of investor it suits, it fits long-term value investors and quality investors better, especially those willing to hold a healthcare-infrastructure business with high compliance barriers for more than ten years; for traditional cigar-butt value investors who only act on a "deeply discounted low valuation," the current price is only moderately attractive. This name does not suit investors who mistake short-term price swings for changes in value.
As for the biggest uncertainties, the three that matter most are: the direction of EO (ethylene oxide) regulation and litigation; whether AST's high margins can be sustained over the long run; and whether, at an already-not-cheap valuation, the growth in intrinsic value per share over the next ten years will be enough to beat the index and high-grade bond alternatives.
Finally, a note on how I tier the evidence. 【Fact】 comes from SEC 10-K / 10-Q / 8-K filings, company proxy statements, the FDA / CDC / EPA / U.S. Census, and market data. 【Assumption】 appears mainly in the valuation: the ratio of maintenance capex to total capex, the long-term growth rate, the discount rate, and the terminal growth rate. 【Inference】 includes things like "switching costs are high," "the moat is stable rather than clearly widening," and "the return at the current price is moderate," which are analytical judgments built on facts. 【Opinion】 covers the final rating, the ideal buy price, and whether it is worth the price. This tiering is not a way to dodge a conclusion; it is a reminder not to treat valuation-model output as fact. Mixing facts, assumptions, and opinions together is one of the most common mistakes in long-term investing.
Understanding the Business and Competitive Landscape
How does this company actually make money? STERIS currently has three continuing-operations segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Healthcare serves hospitals, surgery centers, and endoscopy centers, selling infection-prevention consumables, washing/disinfection and sterilization equipment, equipment maintenance, instrument and endoscope repair, and outsourced reprocessing services; AST serves medical-device and pharmaceutical customers, providing third-party sterilization and lab-testing services and selling integrated sterilization equipment and control systems; Life Sciences serves pharmaceutical and biomanufacturing customers, providing consumables, equipment, maintenance, and professional services related to sterile manufacturing. FY2026 revenue was about $5.936 billion, of which Healthcare $4.209 billion, AST $1.139 billion, and Life Sciences $589 million, a roughly 71% / 19% / 10% revenue split.
Who are the customers, and how does it charge? Healthcare's core customers are hospitals, surgery centers, and endoscopy centers; AST's are medical-device manufacturers and pharmaceutical companies; Life Sciences' are sterile-drug, bioprocessing, and related manufacturing settings. The pricing model is plain: sell equipment, sell consumables, sell maintenance and repair, sell reprocessing/sterilization/lab services. The single most important point for investors is that a fairly high share of this revenue mix comes from recurring services and consumables rather than one-time capital equipment. Based on the FY2025 segment disclosures, services and consumables together make up about 78% of revenue and capital equipment about 22%; this is the foundation of the company's cash-flow stability.
Revenue stability and predictability. The good thing about this business is that it has little to do with "traffic tailwinds" and a lot to do with "whether hospitals need sterilization," "whether device makers need sterilization validation," and "whether sterile drug plants need to meet compliance requirements." The CDC clearly states that "critical items" contacting sterile tissue or the vascular system must be sterilized; the FDA likewise notes that about 50% of sterile medical devices requiring sterilization in the U.S. rely on EO sterilization. In other words, STERIS participates in a link of the healthcare system that is very hard to cut out. Add the continued growth of the U.S. aging population, and the long-term baseline demand for procedure volumes is not weak.
Cost structure and dependencies. This is a business with "decent gross margins, yet not so asset-light that you can ignore the infrastructure." The AST business in particular depends on sterilization facilities, regulatory compliance, validation capability, and long-term operating experience; Healthcare and Life Sciences are more of an "equipment + consumables + services" composite model. Customer concentration is low: the company discloses that in FY2025 no single customer contributed more than 10% of revenue across the three segments. But the supply chain is not risk-free, and the company explicitly warns that some key materials and components have a limited number of suppliers, and that cobalt-60 and EO are even single-sourced in certain regions. For long-term investors, this deserves more attention than "customer concentration."
What stage is the industry in? I classify it as a high-barrier niche within a mature industry. Demand grows over the long run, but not with the explosiveness of pure software; competition is intense, but much of it is not price war so much as validation, regulation, product performance, service responsiveness, customer-workflow lock-in, and global coverage. Competitors in the Healthcare niche include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Olympus, and Stryker; AST goes head-to-head with contract sterilizers such as Sterigenics (Sotera), as well as customers building in-house sterilization capacity.
Long-term industry attractiveness. This is a good company in a good industry, not an outstanding survivor in a bad one. The reasons: first, demand has compliance rigidity; second, end demand does not depend on fashion cycles; third, sterilization and infection prevention are fundamentally the bedrock safeguard of medical safety. The real disruption it faces is not that users suddenly "no longer need sterilization," but that some regulatory, technological, or process shift changes the sterilization method and the distribution of profit. For EO, this is a real risk: in 2024 the EPA tightened EO emission rules for commercial sterilization facilities, affecting nearly 90 facilities; in 2026 it again proposed reconsideration and revision. The industry is not fragile, but the regulatory noise is not low.
My judgment. This business can be understood, but it is not "as simple as Coca-Cola." It has three layers of logic (equipment, consumables, and services, plus outsourced sterilization and life-sciences support) on top of heavy regulatory factors. My scores are:
| Dimension | Score | Judgment |
|---|---|---|
| Business understandability | 4/5 | The difficulty is not "how it makes money," but "how regulation and M&A accounting distort the financials." |
| Industry attractiveness | 4/5 | Long-term demand is stable and regulatory barriers are high, but this is not a risk-free, high-priced industry. |
If the stock market closed for five years, at a better price I would be happy to own this business; at today's price, I am willing to track it, but I would not rush to treat it as an obvious bargain. That distinction matters.
Moat and Management
Where does the moat come from? STERIS's moat comes not mainly from consumer brand, nor from network effects, but from scale, validation, distribution/installed base, service capability, compliance barriers, and customer switching costs. The Healthcare business is not simply selling equipment once; it strings together a hospital's sterile processing, operating rooms, endoscope processing, consumables, maintenance, repair, and outsourced reprocessing into one complete workflow; AST relies on a global network of sterilization facilities and technology-neutral capability. The company discloses that AST operates more than 60 contract sterilization and lab facilities worldwide, which means a new entrant cannot replicate the business just by winning one customer; it must simultaneously solve capacity, compliance, siting, validation, and operations.
A moat-by-moat assessment.
| Moat type | My judgment | Basis |
|---|---|---|
| Brand advantage | Medium | In hospital infection prevention and sterilization infrastructure, brand shows up more as "reliable, compliant, well-serviced" than as a consumer-brand premium. |
| Cost advantage | Locally present | AST's facility density, regulatory experience, and scale utilization can create cost/efficiency advantages, but not an industry-wide lowest-cost monopoly. |
| Scale advantage | Clear | Multiple segments and settings, AST's 60+ facilities worldwide, Healthcare spanning hospital/surgery/endoscopy. |
| Network effects | Weak | Not a platform business. |
| Switching costs | Medium-high | Sterilization validation, process redesign, training, equipment maintenance, audit, and compliance chains make it hard for customers to switch suppliers. |
| Distribution advantage | Medium-high | Installed equipment base, service network, long-term customer relationships, and embedding in hospital workflows create distribution stickiness. |
| Patents/licenses/regulatory barriers | High | Medical, sterilization, and EO-emission regulation itself constitutes an entry barrier. |
| Data advantage | Limited | Not a data-flywheel company. |
| Corporate culture/operating capability | Fairly strong | Able to combine equipment, consumables, services, and compliance operations, essentially an execution-driven capability. |
| Capital-allocation ability | Above average | Consistent dividends, deleveraging, and moderate buybacks, but the goodwill/amortization burden from M&A is also real. |
Is the moat widening, stable, or narrowing? My judgment: overall stable, locally under pressure, not clearly widening. The stable part is that medical procedures, device sterilization, and sterile manufacturing have not been displaced; the part under local pressure is that EO regulation and community-environmental litigation will raise compliance costs and may force process restructuring. Over the past two years the company has still been able to raise prices across segments, showing some pricing power; but in the FY2026 fourth quarter, management also explicitly noted that profit growth in Healthcare and Life Sciences was noticeably partly offset by tariffs and inflation, which shows this is not an infinitely price-raising business.
Can it raise prices in an inflationary environment, and stay profitable in a downturn? It can raise prices, but not frictionlessly. In FY2025 the company disclosed that growth came from higher volumes and price increases across segments; in the FY2026 fourth quarter, segments again showed price improvement. On the other hand, in FY2022 (a year with heavy M&A-integration and accounting distortions) it still delivered positive operating profit and positive operating cash flow, showing that this company is not a fragile model that swings straight to losses once the macro weakens. For a long-term owner, that reliability is important.
Management and governance quality. On governance structure, STERIS's framework is sound: the 2025 proxy discloses that a majority of the board is independent, with an independent chairman, annual director elections, majority voting, no poison pill, a ban on executives and directors hedging/pledging/short-selling the stock, and, since 2023, a clawback policy compliant with the new SEC/NYSE rules. Annual bonus criteria are also centered on 75% Adjusted EBIT + 25% Adjusted FCF, which is directionally aligned with shareholder interests rather than in conflict with them.
Are interests aligned with shareholders? Here I give an "above average," not a "perfect score." The good side: the company has clear stock-ownership requirements, the vast majority of the CEO's pay is variable, and long-term incentives make heavy use of premium options struck at 110% of grant price and restricted stock; the less ideal side: management's ownership does not reach founder-level ultra-high alignment. Per the 2025 proxy, CEO Daniel Carestio holds/has exercisable interests in about 276,800 shares and CFO Michael Tokich about 195,300 shares. This does not mean they are misaligned, but you cannot feel as naturally secure as you would with a family-controlled company.
My overall assessment of management and capital allocation. I give it 4/5. The reason: it has done several shareholder-friendly things in capital allocation (steady dividends, large-scale debt repayment after selling Dental, continued dividends and buybacks in FY2026, and no highly speculative balance sheet); but it has also done large M&A that left a significant goodwill and amortization burden, so I will not praise it as a "master capital allocator." It is more of a competent and fairly steady composite operator than an extremely disciplined, top-tier capital allocator.
Financial Quality and Owner Earnings
The conclusion first. STERIS's financial quality is overall good: revenue grows steadily, gross margin holds around 43%-44%, operating cash flow is strong, deleveraging is clear, and interest coverage is high. Its problem is not that "the earnings are not real," but that post-M&A amortization, restructuring, and discontinued-operations items make the gap between GAAP and adjusted figures wide, so investors can easily be persuaded by "adjusted EPS" while underestimating the optimism baked into the price.
Key financial metrics.
| Fiscal year | Revenue | Gross margin | Operating margin | Net income to parent | Operating cash flow | Free cash flow | Total debt | Cash | Year-end / weighted shares | Dividend per share |
|---|---|---|---|---|---|---|---|---|---|---|
| FY2022† | $4.223B | 44.6% | 11.3% | $244M‡ | $685M§ | $399M§ | See note | See note | See note | 1.69 |
| FY2023 | $4.536B | 43.7% | 17.4% | $107M‡ | $757M | $410M | $3.079B | $208M | Basic weighted 99.706M | 1.84 |
| FY2024 | $5.139B | 43.2% | 16.3% | $378M‡ | $973M | $620M | $3.206B | $207M | Basic weighted 98.787M | 2.03 |
| FY2025 | $5.460B | 44.0% | 15.9% | $615M | $1.148B | $787M | $2.044B | $172M | Basic weighted 98.575M; ~98.301M outstanding at year-end | 2.23 |
| FY2026 | $5.936B | 44.2% | 18.6% | $782M | $1.341B | $983M | $1.932B | $440M | Basic weighted 98.2M; diluted weighted 98.7M | 2.46 |
† FY2022 revenue/margins preferentially use continuing-operations restated data; ‡ Net income to parent for FY2022-FY2024 is significantly affected by discontinued operations, so it cannot be mechanically compared with continuing-operations earnings; § FY2022 cash flow is still on a consolidated basis, including the historical impact of businesses later divested, and is not fully comparable with FY2025-FY2026. The data above come from the FY2024 / FY2025 10-K, the FY2022 10-K, and the FY2026 full-year results announcement, respectively.
Look at growth, not just profit. By the disclosed figures, the FY2022-FY2026 revenue CAGR is about 6.7%; over the same period, operating cash flow rose from $685 million to $1.341 billion, and free cash flow from $399 million to $983 million. Part of this improvement came from procedure-volume growth, pricing, working-capital improvement, and lower interest after deleveraging; it is not purely "revenue rose so cash flow naturally followed." This is exactly why it is not the kind of business where "the more it grows, the more starved for cash it gets."
Is the profit real cash, or accounting profit? Over the past three years, it is closer to real cash. FY2024-FY2026 free cash flow was about $620 million, $787 million, and $983 million, all clearly higher than, or at least no weaker than, net income to parent. FY2025 free cash flow / net income to parent was about 1.28x; FY2026 about 1.26x. This is not a crude proof of "absolute quality," but it at least shows earnings were not propped up by receivables. Management also stated explicitly that FY2026 free-cash-flow growth came mainly from higher net income, even though the working-capital contribution was significantly lower than in FY2025.
Working capital and cash-flow match. FY2025 operating cash flow benefited from better collections and inventory management; in the cash-flow statement, the FY2025 inventory line released $73.07 million of cash and accounts payable increased $33.59 million. At FY2026 year-end, cash rose to $440 million, and receivables, inventory, and payables all increased versus FY2025, consistent with management's note that "the FY2026 working-capital contribution was lower than FY2025." This change looks more like normal operating fluctuation than window-dressing through aggressively stretching payables or stuffing inventory.
Return on capital. Using GAAP operating profit and roughly average invested capital, STERIS's reported ROIC is closer to high-single-digit to low-double-digit, not the no-brainer high returns of a top-tier consumer monopoly; if you look at operating profit and cash returns after stripping out large M&A amortization, the economic return looks somewhat better. FY2026 operating profit was $1.102 billion and interest expense $60.7 million, showing the operating base covers financing costs many times over; FY2025/2026 EBIT interest coverage was roughly 10x / 18x, showing leverage has returned to a comfortable zone. My judgment: returns are decent, but not high enough to ignore the buy price.
The balance sheet. At FY2025 year-end total debt was about $2.044 billion, falling further to about $1.932 billion at FY2026 year-end; over the same period cash rose from $172 million to $440 million, and net debt fell to about $1.49 billion. In FY2025 the company used proceeds from the Dental sale and operating cash to repay $638.1 million of term loans and $80 million of private-placement notes; in FY2026 it repaid a further $125 million of private-placement notes. The company disclosed an FY2025 debt-to-capital ratio of 23.6%, which, using FY2026 year-end debt and equity, has fallen further to about 21%. This balance sheet is now on the steady side.
Accounting and reporting points to watch. First, the gap between adjusted and GAAP is not small. FY2026 "operations before adjustments" (total segment operating profit minus corporate costs) was $1.382 billion, but GAAP operating profit was only $1.102 billion; the largest single adjustment was $265 million of amortization of acquisition-related intangibles. Second, on the balance sheet, goodwill of $4.195 billion + intangibles of $1.620 billion = $5.815 billion, about 54% of total assets. This is not evidence of fraud, but it shows M&A has left a heavy mark on the books, and it means book net assets have limited value as a valuation reference. Third, the company did previously impair and sell the Dental business, so "management's adjusted figures look good" does not equal "every historical capital-allocation decision was excellent."
Owner Earnings. I estimate this on a conservative basis, without gimmicks. The most conservative approach is to treat the company's disclosed free cash flow directly as the lower bound of current-period Owner Earnings, because it has already deducted all capex from operating cash flow, not just maintenance capex. On this basis, conservative FY2026 Owner Earnings is about $983 million. If you further assume that only 80% of that is maintenance capex, the "closer-to-economic-reality" earnings attributable to owners rise to roughly $1.06 billion; but this step already enters the assumption layer and is not a disclosed fact. Given that management's FY2027 guidance explicitly mentions a strategic investment of about $60 million in a new manufacturing site spread over two years, at least this shows that the conservative "total capex = maintenance capex" basis is very likely understating true Owner Earnings over the long run.
How many times Owner Earnings is the current price? At the current market cap of about $21.1 billion and conservative Owner Earnings of $983 million, the current price is about 21.5x conservative Owner Earnings; on my more neutral $1.05 billion basis, it is about 20x. This is not absurdly expensive, but it is absolutely not a bargain price. It is more like "a high-quality company sold at a high-quality price."
Valuation and Margin of Safety
First, what price the market gives it today. As of 2026-05-28/29, STE traded at about $215.4, with a market cap of about $21.1 billion. On FY2026 diluted EPS of $7.93, the trailing P/E is about 27.2x; on FY2026 free cash flow of $983 million and about 98.2 million basic weighted shares, FCF per share is about $10.0, implying 21.5x P/FCF and about a 4.7% FCF yield. FY2026 dividend per share was $2.46, a dividend yield of about 1.1%. Put that yield next to the same day's 4.45% 10-year Treasury and 5.53% Aaa corporate bond, and the conclusion is direct: the market has fairly high confidence in STERIS's growth and quality, so the "return cushion" it leaves for new buyers is not thick.
Method 1: Owner-earnings discounting. Here I use equity-level Owner Earnings, so the valuation result can be read directly as equity value per share, with no further deduction of net debt. The core input is not accounting net income, but the conservative Owner Earnings lower bound of $983 million and a neutral estimate of about $1.05 billion. All three scenarios below are "assumptions," not facts:
| Dimension | Bear | Base | Bull |
|---|---|---|---|
| Starting Owner Earnings/share | $9.7-10.0 | $10.3-10.7 | $10.8-11.2 |
| First-five-year growth | 4% | 6% | 8% |
| Second-five-year growth | 3% | 4% | 5% |
| Discount rate | 9.0% | 8.5% | 8.0% |
| Terminal growth | 2.5% | 3.0% | 3.5% |
| Intrinsic value per share I derive | $160-185 | $190-230 | $240-285 |
The meaning of these results: the current price sits roughly in the upper-middle of the neutral value range. It is neither so overvalued that it should be avoided, nor so undervalued that you should decisively load up. For an investor with a "balanced, somewhat conservative" risk appetite, I weight the lower end of the neutral range more than the upper end. By that standard, today's price lacks the margin that would attract me. From this: Bear intrinsic value range $160-185; fair intrinsic value range $190-230; bull intrinsic value range $240-285. Relative to the current price of $215.4, the company is broadly in a "reasonable but not cheap" state.
Method 2: Relative valuation. For relative valuation I use only companies that are reasonably comparable, though not on fully identical bases, as references. Sotera Health (SHC) is AST's direct contract-sterilization rival, while Stryker (SYK) is a higher-quality, larger medical-device platform company. At current prices, the P/E ratios of STE/SHC/SYK are roughly 30.0x / 38.4x / 35.6x. This shows STE is indeed a bit cheaper than most "premium medical assets," but it is far from a "bargain." More importantly, SHC itself is more affected by litigation and business concentration, so using its higher P/E to justify STE's valuation is not rigorous; SYK is more of what the market sees as a stronger compounding asset. In other words, peers all being expensive does not automatically make STE cheap.
Continuing on STERIS's own basis, it currently trades at 21.5x P/FCF on FY2026 free cash flow; on a rough EV/EBIT using only FY2026 GAAP operating profit of $1.102 billion, enterprise value is also around 20x. All of this shows: you are buying a high-quality business, but not a discounted asset.
Method 3: Asset or liquidation value. This company is not suited to a liquidation-value approach. At FY2026 year-end, total assets were about $10.737 billion, of which goodwill $4.195 billion and intangibles $1.620 billion, together over $5.8 billion; total equity was about $7.197 billion. Roughly, tangible net assets are only on the order of $1.3-1.4 billion, far from the current market cap of $21.1 billion. That is, the market is paying for this company's future cash flows and moat, not for readily saleable physical assets. For a long-term investor this is fine, but it means: there is no asset safety cushion, so the price must make enough sense on its own.
Is the margin of safety enough? My judgment: not sufficient. The most fragile assumption is not "whether the company will grow," but "whether the company can still deliver a good enough 10-year shareholder return in an environment where EO regulation and a fairly high valuation both exist." If over the next ten years it only achieves 3%-4% Owner-Earnings growth and the valuation falls back to 18-20x Owner Earnings, the annualized return on buying today would land at a mild level, not necessarily clearly better than the index. If growth is lower, AST margins fall below 40%, or new M&A drags down returns, you could even end up with "the company is still fine, but the investment return is quite ordinary." For long-term capital, that is still a loss.
Price-range guidance.
| Range | My judgment |
|---|---|
| $165-190 | Closer to the range where I would pay for a 10-year hold; leaves at least a 10%-20% cushion to neutral value. |
| $190-235 | Can hold and watch, but not clearly undervalued. |
| $255 and above | For a conservative investor, this begins to enter the clearly-overvalued / insufficient-return zone. |
So the question is whether you are willing to own it without an obvious margin of safety, rather than whether STERIS is worth owning. My answer: existing holders can keep holding, and those who don't own it are better off waiting.
Risks, Comparisons, and Final Checklist
The most important risks.
| Risk | Why it matters |
|---|---|
| EO regulatory and litigation risk | The FDA still notes that about 50% of sterile medical devices rely on EO; the EPA tightened EO emission rules for commercial sterilization facilities in 2024 and proposed revision/reconsideration in 2026; STERIS also explicitly warns that changes in EO regulation could significantly affect costs and operations. |
| Competition risk | Healthcare faces multi-party competition from Getinge, Ecolab, Olympus, Stryker, and others; AST faces Sterigenics (Sotera) directly, plus customers' in-house capacity. |
| Technology-substitution risk | Sterilization methods may partly migrate from EO to e-beam, x-ray, VHP, etc., but migration is constrained by material compatibility, validation processes, and regulation, and will not happen overnight. |
| Overvaluation risk | The current FCF yield is not far above the 10-year Treasury; if growth or margins fall short, valuation compression would significantly drag on returns. |
| M&A and amortization burden | Goodwill and intangibles are a high share of assets, and FY2026 intangible amortization still reached $265 million; if large acquisitions return poorly, they erode true ROIC. |
| Supply-chain and key-input risk | The company discloses that cobalt-60 and EO supply is limited or even single-sourced in certain regions. |
| Macro/policy and cost risk | In the FY2026 fourth quarter, management already flagged a noticeable offsetting effect from tariffs and inflation on profit. |
| Accounting-basis misjudgment risk | The gap between adjusted and GAAP is not small; looking only at adjusted EPS makes it easy to underestimate true capital intensity and M&A costs. |
The strongest bear case. The most powerful bear argument is not "this is a bad company," but: this is a high-quality but already-not-cheap, regulation-sensitive composite business. A bear would say you are paying close to a premium-medical-asset valuation today, but what you get is not a regulation-free, uncontested consumer monopoly; it is a company with real EO risk, a not-low goodwill-and-amortization ratio, returns that are not top-tier, and a need for continued execution and capital discipline to sustain quality. If just two things happen over the next 3-5 years, growth slowing and the valuation reverting to that of an ordinary good company, the investment result could be mediocre. I think this bear case carries weight.
Which facts would overturn my investment judgment. If the following facts appear, I would consider the original investment logic broken and would have to admit I was wrong: first, AST's regulatory costs or litigation pressure keep rising, driving its long-term operating margin to stably fall below 40%; second, group organic growth falls to below 4% over the long run while it still sustains high-valuation buybacks or high-priced M&A; third, net debt rises again and capital allocation reverts to "chasing scale rather than per-share value"; fourth, a large new goodwill impairment appears, proving prior M&A returns fell short. Any one of these would materially damage the "high-quality compounder" label.
Compared with other opportunities, is it worth the capital? Versus its direct rival SHC, I favor STERIS: the business is more diversified, the customer base is steadier, the balance sheet is healthier, and beyond contract sterilization it has two more legs in Healthcare and Life Sciences. Versus the stronger medical-platform company SYK, STERIS is slightly cheaper, but not cheap enough to constitute a clear "value-for-money advantage." Versus the index, STERIS's advantages are its industry barriers and understandability, and its disadvantage is single-company risk; versus the 10-year Treasury or high-grade corporate bonds, its advantage can only come from future growth, not from today's yield. For a balanced, somewhat conservative portfolio, this means: if you could only hold five assets, STE is not yet cheap enough to lock in a top-five spot.
Investment Checklist.
| Item | Conclusion | Comment |
|---|---|---|
| Can I understand this business? | Pass | Equipment, consumables, services, contract sterilization; the logic is clear. |
| Does it have long-term stable demand? | Pass | Medical procedures, device sterilization, and sterile drug production all have long-term rigidity. |
| Does it have a durable moat? | Pass | But more "stable" than "rapidly widening." |
| Does it have pricing power? | Pass | Yes, but affected by tariffs, inflation, and regulation. |
| Can it generate stable free cash flow? | Pass | Strongly validated across FY2024-FY2026. |
| Is its return on capital excellent? | Uncertain | Decent on a reported basis but not top-tier; the cash basis beats GAAP. |
| Is management trustworthy? | Pass | Sound governance and reasonable incentive direction, but not founder-level ultra-strong alignment. |
| Is capital allocation rational? | Pass | Dividends, debt repayment, moderate buybacks all fine; the M&A burden still needs monitoring. |
| Is the balance sheet sound? | Pass | Clear deleveraging and high interest coverage. |
| Is the valuation below intrinsic value? | Fail | More like fair value than a discounted buy. |
| Is the margin of safety enough? | Fail | Not enough for a conservative investor. |
| Does long-term holding let me sleep well? | Pass | Provided the buy price is more reasonable. |
| Which facts would make me sell? | Clear | AST regulation worsening, a step-down in growth/margins, a return of high-priced M&A. |
| Am I only tempted to buy because of price action or emotion? | Be cautious | Right now it is easier to be swayed by the "good company narrative" than by a "cheap price." |
Final Investment Conclusion.
【Final Rating】 Watch
【One-Sentence Investment Thesis】 STERIS is an understandable healthcare-infrastructure business with solid cash flow and a fairly stable moat, but buying at today's price means you are getting a good company, not an obviously cheap one.
【Core Bull Case】
Services and consumables are a high share of the revenue mix, giving better durability and predictability than a pure-equipment company.
The AST business has high regulatory and facility barriers, with an FY2026 segment operating margin of about 46.1%.
Free cash flow is consistently strong, reaching $983 million in FY2026; the company can pay dividends, buy back stock, and keep deleveraging all at once.
Customers are diversified, with no single customer above 10%, giving the business model good resilience.
Underlying demand comes from infection prevention, device sterilization, and sterile manufacturing, giving high long-term demand quality.
【Core Bear Case】
The current valuation is not low, with an FY2026 FCF yield of about 4.7%, only slightly above the 10-year Treasury, so the margin of safety is insufficient.
EO regulatory and litigation risk is a real, high-impact variable, not a peripheral one.
M&A has left a heavy goodwill-and-intangibles amortization burden, with a wide gap between GAAP and adjusted figures.
Management ownership is not at a "super-high alignment" level, and capital allocation, while competent, is not excellent enough to ignore the buy price.
It could be a "good company at a bad price," and this kind of mistake does great damage to long-term returns.
【Key Assumptions】
AST's regulatory costs stay manageable, and long-term margins broadly hold at 40%+.
The company's Owner Earnings growth over the next 10 years stays in the mid-to-high single digits.
Management does not pursue high-valuation, low-return large acquisitions.
Free cash flow continues to clearly cover dividends and regular buybacks.
【Fair Buy Price】 My preferred buy range is $165-190. The basis is not a guess but three things stacked together: the lower end of the conservative DCF, a more comfortable entry point of 18-19x FCF, and leaving a cushion for EO/M&A/valuation-reversion.
【Target Holding Period】 More than 10 years. This name does not suit a 12-month holding period, because in the short run price is driven mainly by valuation swings and sentiment rather than by the realization of intrinsic value.
【Expected Annualized Return】 At the current price, I give a restrained three-scenario estimate:
Bear scenario: 3%-5%
Base scenario: 6%-8%
Bull scenario: 9%-11%
This already factors in dividends, moderate buybacks, and long-term growth; if the valuation compresses noticeably, even the base return could shift lower.
【Maximum Loss Risk】 I think the realistic "bad but not extreme" scenario is a 30%-40% price decline, corresponding to slowing growth, rising regulatory costs, and the valuation falling back to the range of an ordinary good company. A worse "extreme scenario" (for example, EO regulation deteriorating significantly, AST facilities being constrained, litigation costs rising, compounded by mistaken M&A) could in theory bring a permanent capital loss of more than 50%. What deserves the most caution here is not short-term volatility, but buying at a high price, then having business quality dip slightly while the valuation reverts at the same time.
【Tracking Metrics】 Going forward, I will keep watching these signals: first, constant-currency organic growth by segment; second, AST segment margin; third, operating cash flow and free cash flow; fourth, working-capital changes; fifth, net debt and interest coverage; sixth, whether price increases can offset inflation and tariffs; seventh, buyback amounts and buyback prices; eighth, the price and return of new acquisitions; ninth, EO regulatory and litigation progress; tenth, whether goodwill/intangibles show new signs of impairment.
【Signals That Trigger Reassessment】
AST margin steps down noticeably for several consecutive quarters;
organic growth falls to low single digits with no sign of recovery;
EO-related compliance capex and litigation reserves rise noticeably;
a high-priced large acquisition is launched again;
FCF is weaker than net income for consecutive periods, with deteriorating working capital;
buybacks occur while clearly overvalued, looking more like "dressing up per-share metrics" than value-accretive repurchase.
【Open questions / limitations】 The detailed financial breakdown in this report is based mainly on the FY2025 10-K and the FY2026 full-year results announcement / 8-K. I have not further developed the complete FY2026 10-K or the updated FY2026 proxy from the materials obtained, so items such as the precise breakdown of full-year FY2026 D&A, the latest executive holdings, and precise maintenance capex still carry basis limitations. The relative-valuation section, because comparable companies are on different business bases, can only be a "directional comparison" and should not be applied mechanically.
【Final Recommendation】 Coolly put, STERIS belongs on your long-term watchlist, and even qualifies as one of the standard answers for a "high-quality healthcare-infrastructure stock"; but for a balanced, somewhat conservative long-term value investor, the more important action today is to wait with discipline for the price to offer better odds, rather than to buy immediately. My final stance is simple: the business passes; the price does not, for now.
This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.
Full report
Sign in to read the full report
Sign up free to unlock the full text, the Baillie growth scorecard, and full-text search.
Log in / Sign up free